Surplus Is Not Cash: A UK Equity Analyst's Guide to DB Buy-Out Disclosures

UK defined benefit (DB) schemes are reporting some of their strongest funding positions in years. That has encouraged sponsors to pursue buy-ins, buy-outs and other endgame transactions. For equity analysts, the temptation is to treat a disclosed surplus as a source of shareholder value. The better discipline is to treat it as a claim that must be traced through scheme rules, trustee discretion, insurer pricing and accounting recognition. In 2026, as more FTSE 350 sponsors announce bulk annuity transactions, the distinction between an actuarial surplus and cash liberation is central to valuation work.

Begin with the basis of the surplus

A pension surplus is not a single number. It depends on the assumptions used. Accounting surpluses under IAS 19 use corporate bond yields, inflation expectations and mortality assumptions. Trustee funding surpluses use the scheme's technical provisions and the sponsor covenant. Buy-out surpluses use an insurer's pricing basis, which reflects capital costs, expenses and risk margins. These bases can diverge materially.

The first analytical step is therefore to identify which basis is being disclosed. An IAS 19 surplus on the balance sheet may be subject to an asset ceiling and may not be recoverable. A funding surplus in the trustee's actuarial valuation may still leave a deficit on a buy-out basis. A buy-out quotation may show a surplus only after restructuring benefits, or may require an additional sponsor contribution. Analysts should look for the valuation date, the discount rate, the inflation assumption and the mortality table. If the company does not disclose them, the annual report, trustee report and actuarial valuation summaries are the place to start.

The three ledgers

It helps to separate three ledgers.

The accounting ledger records the IAS 19 position and any irrecoverable surplus. The funding ledger records the trustee's technical provisions, the schedule of contributions and the recovery plan. The transaction ledger records the insurer's premium, assets transferred, residual risks and any deferred or contingent payments.

Only the third ledger can show whether a buy-out is genuinely cash-liberating for the sponsor. Even then, the surplus may not flow to the company. Scheme rules may require it to be used for member benefits, expenses or a winding-up process. Trustee consent is usually needed. Tax and regulatory constraints may apply. A buy-out can reduce risk without releasing cash.

Read the disclosure like a deal document

Buy-in and buy-out disclosures are often brief. The analyst should extract a small set of facts. What is the transaction structure? Is it a buy-in, where the trustee holds an insurance policy, or a buy-out, where liabilities and assets transfer to an insurer? What premium was paid? Which assets were transferred? Is the sponsor retaining any residual exposure, such as deferred premiums, escrow arrangements or guarantees? Is there a surplus-sharing mechanism?

The wording matters. 'Agreement in principle' is not completion. 'Full scheme buy-in' is not a buy-out. 'Self-sufficiency' is not the same as 'surplus'. Companies may highlight a funding surplus while disclosing a buy-out deficit in the same announcement. Analysts should reconcile the two rather than accept the headline.

Five tests before revising forecasts

A practical framework has five tests.

First, reconcile the bases. Compare the IAS 19 surplus, the trustee funding surplus and any buy-out quotation. Identify the assumption differences.

Second, trace the route to cash. Ask whether the sponsor can access the surplus through a contribution holiday, reduced deficit contributions, a refund or a winding-up distribution. Check the scheme rules and trustee policy.

Third, test the insurer's price. Bulk annuity pricing reflects longevity, liquidity and capital. A quoted surplus can disappear if the insurer's assumptions change before completion.

Fourth, map residual exposures. Buy-ins leave the trustee and sponsor with governance, expense and counterparty risks. Buy-outs may leave residual liabilities, warranties or indemnities.

Fifth, read governance signals. Trustee board changes, actuarial adviser switches, sponsor covenant disclosures and The Pensions Regulator's involvement can all signal whether a surplus is robust. A scheme that is being prepared for buy-out may have different incentives from one that is still in recovery.

From disclosure to valuation

Equity analysts should not capitalise a pension surplus as if it were cash. A more defensible approach is to value it as a contingent asset. Estimate the probability of cash release, the timing and the amount. Apply a haircut for trustee discretion, tax, expenses and residual risk. If the company has already assumed a contribution holiday in guidance, quantify the cash flow benefit separately. If the surplus is only actuarial, leave forecasts unchanged until the transaction is completed and the cash route is clear.

The 2022 LDI episode is a reminder that pension positions can change quickly. A funding surplus is sensitive to gilt yields, inflation and insurer capacity. The governance lesson is to ask for the scheme's funding basis, the trustee's endgame plan and the sponsor's legal ability to extract value. Those questions are more useful than a single surplus figure.

Conclusion

The UK DB buy-out wave is a genuine development for corporate balance sheets. It can reduce risk and improve clarity for shareholders. But a surplus on an actuarial valuation is not the same as cash in the sponsor's hands. Analysts who distinguish the accounting, funding and transaction ledgers, and who test the governance route to cash, will be better placed to judge whether a buy-out announcement changes equity value or merely changes the risk profile.

For CFA UK Review readers, the discipline is familiar: read the disclosure, challenge the basis and separate probability from headline. The pension surplus may be real. The cash liberation is the question.